Tilray Brands, Inc. Common Stock
TLRYTilray Brands, Inc. is a global leader in the production and distribution of medical cannabis, adult-use cannabis, and wellness products. Founded in 2013, the company operates through various subsidiaries and brands, offering a range of cannabis products, including cannabis flowers, oils, and edibles, to both medical and recreational markets worldwide. Tilray emphasizes research, quality, and innovation within the rapidly evolving cannabis industry.
Company News
Several major companies are reporting earnings this week as markets navigate a complex start to 2026. Applied Digital will report Q2 results Wednesday after market close with expected revenue of $87.51 million. Tilray Brands will report Q2 2026 results Thursday after market close with expected revenue of $210.95 million, with investors watching f...
Cannabis stocks like Tilray Brands and Curaleaf Holdings have surged following President Trump's executive order reclassifying cannabis as Schedule 3. While this regulatory change could improve banking access and tax treatment for multistate operators, the author cautions that the rally may be short-lived due to stringent state regulations, high ...
Cannabis stocks have sold off despite President Trump's December 2025 Executive Order directing cannabis rescheduling, creating a potential contrarian opportunity. Moving cannabis from Schedule I to Schedule III would eliminate IRS Section 280E, effectively removing a 70%+ tax burden on operators and transforming industry profitability. Canopy Gr...
Tilray Brands announced it will release its second fiscal quarter financial results (ended November 30, 2025) on January 8, 2026, followed by a live conference call at 4:30 PM ET. The company will also host an investor Q&A session via Robinhood and Say Technologies platforms.
Tilray Brands reported Q4 2024 revenue of $229.88 million, up 24.8% year-over-year, and EPS of -$0.04 compared to $0.00 in the prior year. The company's performance was mixed compared to analyst estimates, with revenue beating expectations but EPS missing.
